Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + olaparib vs single-agent chemotherapy in platinum-resistant/refractory high-grade serous ovarian cancer without germline BRCA mutation
jRCT2031210106Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of alpelisib and olaparib in High-Grade Serous Ovarian Cancer (HGSOC), Endometrioid Cystadenocarcinoma, fallopian tube cancer (PFTC) and 1 more (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival (PFS). Started Mar 2022; status: completed.
02
Drugs
alpelisibolaparib
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)Endometrioid Cystadenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2031210106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210106.